ViiV Healthcare HIV Treatment Cabenuva Meets Primary Endpoint in Phase IIIb Study

ViiV Healthcare announced its long-acting HIV treatment, Cabenuva (cabotegravir + rilpivirine), met the primary endpoint of the phase IIIb CROWN study. At six months, the treatment demonstrated superior viral suppression compared to daily oral therapy in individuals with viremia.